<DOC>
	<DOCNO>NCT01296659</DOCNO>
	<brief_summary>Ridaforolimus test almost 2 dozen study ; however , previously test combination standard care chemotherapy sarcoma study . We look see Ridaforolimus give SOC chemo ( AIM TG ) well tolerate determine Phase 2 dose .</brief_summary>
	<brief_title>Study Oral Ridaforolimus Combination With Standard Chemotherapy Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Advanced metastatic soft tissue sarcoma histological cytological proven disease . No 2 line chemotherapy metastatic set dose escalation phase , one line prior therapy expansion phase . ECOG performance status ≤ 1 A minimum life expectancy &gt; 3 month At least 4 week must elapse prior investigational therapy , chemotherapy radiotherapy first dose ridaforolimus Adequate hematological , hepatic renal function ( hemoglobin ≥ 9g/dl , absolute neutrophil count [ ANC ] ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L ; bilirubin ≤ ULN ; alkaline phosphatase ≤ 2.5 x ULN ; AST , ALT ≤ 2.5 x ULN ; albumin ≥ 2.5mg/dL ; creatinine ≤ 1.5 x ULN ) Serum cholesterol ≤ 350 mg/dL triglyceride ≤400 mg/dL Signed informed consent Women childbearing potential must negative serum pregnancy test within 7 day prior start therapy must use approved contraceptive method appropriate time screen 30 day last dose study drug . Uncontrolled brain metastasis , spinal cord compression , carcinomatous meningitis . Clinically significant unexplained bleed within 28 day prior enter trial Uncontrolled systemic vascular hypertension Clinically significant cardiovascular disease Newly diagnose ( within 3 month enrollment ) poorly control type 1 2 diabetes Have receive &gt; 350 mg/m2 total dose Doxorubicin Active infection require prescribe intervention Other concurrent illness Major surgery within 28 day trial entry , incompletely heal surgical incision ; minor surgery procedure within 7 day Previous anthracycline lifetime exposure 350 mg/m2 would exclude patient form AIM Arm enrollment Pregnant breastfeed Known allergy macrolide antibiotic Concurrent treatment medication induce inhibit cytochrome P450 ( CYP3A ) . Known history HIV seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>Ridaforolimus</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>unresectable sarcoma</keyword>
</DOC>